Biotech Values

[DewDiligence]

GSK/THRX—“Analysts on average expect Anoro Ellipta to generate annual sales of about $2.65 billion and Breo Ellipta of about $2.22 billion by 2018, according to Thomson Reuters data.”

http://in.reuters.com/article/2013/12/18/us-gsk-fda-lungdrug-idINBRE9BH0WW20131218

I don’t think the comparison will be that close; rather, I expect Anoro Ellipta will handily outsell Breo/Relvar Ellipta on a worldwide basis including all indications.